Release Details

SAN DIEGO, Feb. 9 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Bruce Campbell, Ph.D. to the newly created position of Vice President of Development. In this capacity, Dr. Campbell will be responsible directing Neurocrine's selection and advancement of drug candidates from research into clinical development. Neurocrine currently has three drug candidates in various phases of clinical development.

Dr. Campbell joins Neurocrine after 27 years at Servier United Kingdom (U.K.), a subsidiary of an international pharmaceutical company based in France, where he served as Director of International Scientific Affairs since 1991. In this capacity he had worldwide responsibility as liaison with regulatory agencies and academic institutions, and was involved in the development of several new drug registrations, including the development of dexfenfluramine throughout the world. Earlier as Research Director he set up a Biodisposition and clinical pharmacology group and was responsible for the development and registration of more than 8 drugs and vaccines in the U.K. and English speaking countries.

Dr. Campbell is the present European Chairman of the Drug Information Association, is a member of the ICH Safety Working Party and meetings secretary of the Society for Pharmaceutical Medicine, and is a visiting Professor in Pharmacology at Kings College London. He is recognized as one of the experts on the regulatory aspects of kinetics and toxicology in new drug development and has written standard texts on the subject. Dr. Campbell is also on the editorial board of International journals and a member of many scientific societies and has published more than 100 papers.

"We are pleased to welcome Dr. Campbell to Neurocrine during our pivotal transition from research into clinical development. We plan to advance several new products into clinical development and are fortunate to have someone of Bruce's expertise to enhance our drug development capabilities," said Gary A. Lyons, President and Chief Executive Officer of Neurocrine Biosciences.

Neurocrine Biosciences is a leading neuroimmunolgy company focused on the discovery and development of novel therapeutics to treat diseases and disorders of the central nervous and immune system such as anxiety, depression, Alzheimer's disease, obesity and multiple sclerosis.

The statements in this press release that relate to the advancement of potential products into clinical development, the continuation of clinical trials of the Company's development candidates, and the potential development of commercial products are forward looking statements. Such forward looking statements involve risks and uncertainties, including, without limitation, that development will continue under Neurocrine's strategic partnerships in a timely manner consistent with Neurocrine's objectives, that development candidates will successfully proceed through early stage clinical trials, that development candidates will prove effective for treatment in humans in later stage clinical trials, the timely receipt of regulatory clearances required for clinical testing, manufacturing and marketing of products and the potential impact of competitive technologies and potential products. For a discussion of the other risks and uncertainties potentially affecting the Company, see the Company's form 10K for the year ending December 31, 1996. Actual results and the timing of certain events could differ materially from those indicated in the forward looking statements as a result of these and other factors.
SOURCE Neurocrine Biosciences, Inc.
CONTACT: Elizabeth Foster or Paul Hawran, both of Neurocrine Biosciences, 619-658-7600 CNOC: http: //www.prnewswire.com or fax, 800-758-5804, ext. 604138